Lynch syndrome: A primer for urologists and panel recommendations

Maureen Mork, Scott G. Hubosky, Morgan Rouprêt, Vitaly Margulis, Jay Raman, Yair Lotan, Timothy O'Brien, Nancy You, Shahrokh F. Shariat, Surena F. Matin

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

Purpose Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is a common genetic disease. The predisposition of patients with Lynch syndrome to urological cancer, particularly upper tract urothelial carcinoma, is underappreciated. Urologists may be involved in several aspects of care involving Lynch syndrome, including identifying undiagnosed patients, surveillance of those with established Lynch syndrome or screening family members, in addition to treating patients with Lynch syndrome in whom upper tract urothelial carcinoma develops. We sought to increase awareness in the urological community about Lynch syndrome and provide some guidance where little currently exists. Materials and Methods Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement we reviewed the available published literature and guidelines from 1998 to 2014 on Lynch syndrome and its association with upper tract urothelial carcinoma. Recommendations based on the literature and the consensus of expert opinion are provided. Results No randomized or prospective study has been done to evaluate Lynch syndrome in the setting of urological cancer. All data were based on retrospective studies. Lynch syndrome is an autosomal dominant genetic disease caused by germline mutations in 4 mismatch repair genes, leading to the accumulation of DNA errors in microsatellite regions. Upper tract urothelial carcinoma develops in up to 28% of patients with known Lynch syndrome. The diagnosis of Lynch syndrome is established by clinical criteria, tumor tissue testing and genetic evaluation. Urologists should suspect Lynch syndrome when a patient with upper tract urothelial carcinoma presents before age 60 years or meets the 3-2-1 rule. Screening patients with Lynch syndrome for upper tract urothelial carcinoma presents a particular challenge. While no ideal screening test exists, at a minimum routine urinalysis is recommended using the American Urological Association guideline of 3 or more red blood cells per high power field as a trigger for further assessment. Upper tract urothelial carcinoma associated with Lynch syndrome presents at a younger age than sporadic upper tract urothelial carcinoma. It shows a higher proportion of ureteral cancer with a female preponderance and a possible predisposition to bilaterality. Conclusions Lynch syndrome is a common genetic disease that is an underappreciated cause of upper tract urothelial carcinoma and possibly other urological cancers. Optimal screening for upper tract urothelial carcinoma in this population is unclear. Further study is needed to identify the best screening test and interval of testing. Urologists should consider routine tissue testing of de novo upper tract urothelial carcinoma tissue in individuals at risk.

Original languageEnglish (US)
Pages (from-to)21-29
Number of pages9
JournalJournal of Urology
Volume194
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Carcinoma
Urologic Neoplasms
Inborn Genetic Diseases
Urologists
Ureteral Neoplasms
Guidelines
DNA Mismatch Repair
Urinalysis
Germ-Line Mutation
Expert Testimony
Genetic Testing

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Mork, M., Hubosky, S. G., Rouprêt, M., Margulis, V., Raman, J., Lotan, Y., ... Matin, S. F. (2015). Lynch syndrome: A primer for urologists and panel recommendations. Journal of Urology, 194(1), 21-29. https://doi.org/10.1016/j.juro.2015.02.081
Mork, Maureen ; Hubosky, Scott G. ; Rouprêt, Morgan ; Margulis, Vitaly ; Raman, Jay ; Lotan, Yair ; O'Brien, Timothy ; You, Nancy ; Shariat, Shahrokh F. ; Matin, Surena F. / Lynch syndrome : A primer for urologists and panel recommendations. In: Journal of Urology. 2015 ; Vol. 194, No. 1. pp. 21-29.
@article{d5b370f06c9f4d1990aaed6becc8eb0a,
title = "Lynch syndrome: A primer for urologists and panel recommendations",
abstract = "Purpose Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is a common genetic disease. The predisposition of patients with Lynch syndrome to urological cancer, particularly upper tract urothelial carcinoma, is underappreciated. Urologists may be involved in several aspects of care involving Lynch syndrome, including identifying undiagnosed patients, surveillance of those with established Lynch syndrome or screening family members, in addition to treating patients with Lynch syndrome in whom upper tract urothelial carcinoma develops. We sought to increase awareness in the urological community about Lynch syndrome and provide some guidance where little currently exists. Materials and Methods Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement we reviewed the available published literature and guidelines from 1998 to 2014 on Lynch syndrome and its association with upper tract urothelial carcinoma. Recommendations based on the literature and the consensus of expert opinion are provided. Results No randomized or prospective study has been done to evaluate Lynch syndrome in the setting of urological cancer. All data were based on retrospective studies. Lynch syndrome is an autosomal dominant genetic disease caused by germline mutations in 4 mismatch repair genes, leading to the accumulation of DNA errors in microsatellite regions. Upper tract urothelial carcinoma develops in up to 28{\%} of patients with known Lynch syndrome. The diagnosis of Lynch syndrome is established by clinical criteria, tumor tissue testing and genetic evaluation. Urologists should suspect Lynch syndrome when a patient with upper tract urothelial carcinoma presents before age 60 years or meets the 3-2-1 rule. Screening patients with Lynch syndrome for upper tract urothelial carcinoma presents a particular challenge. While no ideal screening test exists, at a minimum routine urinalysis is recommended using the American Urological Association guideline of 3 or more red blood cells per high power field as a trigger for further assessment. Upper tract urothelial carcinoma associated with Lynch syndrome presents at a younger age than sporadic upper tract urothelial carcinoma. It shows a higher proportion of ureteral cancer with a female preponderance and a possible predisposition to bilaterality. Conclusions Lynch syndrome is a common genetic disease that is an underappreciated cause of upper tract urothelial carcinoma and possibly other urological cancers. Optimal screening for upper tract urothelial carcinoma in this population is unclear. Further study is needed to identify the best screening test and interval of testing. Urologists should consider routine tissue testing of de novo upper tract urothelial carcinoma tissue in individuals at risk.",
author = "Maureen Mork and Hubosky, {Scott G.} and Morgan Roupr{\^e}t and Vitaly Margulis and Jay Raman and Yair Lotan and Timothy O'Brien and Nancy You and Shariat, {Shahrokh F.} and Matin, {Surena F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.juro.2015.02.081",
language = "English (US)",
volume = "194",
pages = "21--29",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1",

}

Mork, M, Hubosky, SG, Rouprêt, M, Margulis, V, Raman, J, Lotan, Y, O'Brien, T, You, N, Shariat, SF & Matin, SF 2015, 'Lynch syndrome: A primer for urologists and panel recommendations', Journal of Urology, vol. 194, no. 1, pp. 21-29. https://doi.org/10.1016/j.juro.2015.02.081

Lynch syndrome : A primer for urologists and panel recommendations. / Mork, Maureen; Hubosky, Scott G.; Rouprêt, Morgan; Margulis, Vitaly; Raman, Jay; Lotan, Yair; O'Brien, Timothy; You, Nancy; Shariat, Shahrokh F.; Matin, Surena F.

In: Journal of Urology, Vol. 194, No. 1, 01.01.2015, p. 21-29.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lynch syndrome

T2 - A primer for urologists and panel recommendations

AU - Mork, Maureen

AU - Hubosky, Scott G.

AU - Rouprêt, Morgan

AU - Margulis, Vitaly

AU - Raman, Jay

AU - Lotan, Yair

AU - O'Brien, Timothy

AU - You, Nancy

AU - Shariat, Shahrokh F.

AU - Matin, Surena F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is a common genetic disease. The predisposition of patients with Lynch syndrome to urological cancer, particularly upper tract urothelial carcinoma, is underappreciated. Urologists may be involved in several aspects of care involving Lynch syndrome, including identifying undiagnosed patients, surveillance of those with established Lynch syndrome or screening family members, in addition to treating patients with Lynch syndrome in whom upper tract urothelial carcinoma develops. We sought to increase awareness in the urological community about Lynch syndrome and provide some guidance where little currently exists. Materials and Methods Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement we reviewed the available published literature and guidelines from 1998 to 2014 on Lynch syndrome and its association with upper tract urothelial carcinoma. Recommendations based on the literature and the consensus of expert opinion are provided. Results No randomized or prospective study has been done to evaluate Lynch syndrome in the setting of urological cancer. All data were based on retrospective studies. Lynch syndrome is an autosomal dominant genetic disease caused by germline mutations in 4 mismatch repair genes, leading to the accumulation of DNA errors in microsatellite regions. Upper tract urothelial carcinoma develops in up to 28% of patients with known Lynch syndrome. The diagnosis of Lynch syndrome is established by clinical criteria, tumor tissue testing and genetic evaluation. Urologists should suspect Lynch syndrome when a patient with upper tract urothelial carcinoma presents before age 60 years or meets the 3-2-1 rule. Screening patients with Lynch syndrome for upper tract urothelial carcinoma presents a particular challenge. While no ideal screening test exists, at a minimum routine urinalysis is recommended using the American Urological Association guideline of 3 or more red blood cells per high power field as a trigger for further assessment. Upper tract urothelial carcinoma associated with Lynch syndrome presents at a younger age than sporadic upper tract urothelial carcinoma. It shows a higher proportion of ureteral cancer with a female preponderance and a possible predisposition to bilaterality. Conclusions Lynch syndrome is a common genetic disease that is an underappreciated cause of upper tract urothelial carcinoma and possibly other urological cancers. Optimal screening for upper tract urothelial carcinoma in this population is unclear. Further study is needed to identify the best screening test and interval of testing. Urologists should consider routine tissue testing of de novo upper tract urothelial carcinoma tissue in individuals at risk.

AB - Purpose Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is a common genetic disease. The predisposition of patients with Lynch syndrome to urological cancer, particularly upper tract urothelial carcinoma, is underappreciated. Urologists may be involved in several aspects of care involving Lynch syndrome, including identifying undiagnosed patients, surveillance of those with established Lynch syndrome or screening family members, in addition to treating patients with Lynch syndrome in whom upper tract urothelial carcinoma develops. We sought to increase awareness in the urological community about Lynch syndrome and provide some guidance where little currently exists. Materials and Methods Using the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement we reviewed the available published literature and guidelines from 1998 to 2014 on Lynch syndrome and its association with upper tract urothelial carcinoma. Recommendations based on the literature and the consensus of expert opinion are provided. Results No randomized or prospective study has been done to evaluate Lynch syndrome in the setting of urological cancer. All data were based on retrospective studies. Lynch syndrome is an autosomal dominant genetic disease caused by germline mutations in 4 mismatch repair genes, leading to the accumulation of DNA errors in microsatellite regions. Upper tract urothelial carcinoma develops in up to 28% of patients with known Lynch syndrome. The diagnosis of Lynch syndrome is established by clinical criteria, tumor tissue testing and genetic evaluation. Urologists should suspect Lynch syndrome when a patient with upper tract urothelial carcinoma presents before age 60 years or meets the 3-2-1 rule. Screening patients with Lynch syndrome for upper tract urothelial carcinoma presents a particular challenge. While no ideal screening test exists, at a minimum routine urinalysis is recommended using the American Urological Association guideline of 3 or more red blood cells per high power field as a trigger for further assessment. Upper tract urothelial carcinoma associated with Lynch syndrome presents at a younger age than sporadic upper tract urothelial carcinoma. It shows a higher proportion of ureteral cancer with a female preponderance and a possible predisposition to bilaterality. Conclusions Lynch syndrome is a common genetic disease that is an underappreciated cause of upper tract urothelial carcinoma and possibly other urological cancers. Optimal screening for upper tract urothelial carcinoma in this population is unclear. Further study is needed to identify the best screening test and interval of testing. Urologists should consider routine tissue testing of de novo upper tract urothelial carcinoma tissue in individuals at risk.

UR - http://www.scopus.com/inward/record.url?scp=84940669443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940669443&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.02.081

DO - 10.1016/j.juro.2015.02.081

M3 - Review article

C2 - 25711197

AN - SCOPUS:84940669443

VL - 194

SP - 21

EP - 29

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1

ER -